Galena Biopharma (NASDAQ:GALE) has been rated by 4 research analysts. Fundamentally, the highest shorterm price forecast for the stock is expected to reach $5 and the lowest price target forecast is $4. The average forecast of all the analysts is $4.38 and the expected standard deviation is $0.75.
Galena Biopharma, Inc. has lost 78.32% in the last five trading days and dropped 78.42% in the last 4 weeks. Galena Biopharma, Inc. has dropped 68.72% during the last 3-month period . Year-to-Date the stock performance stands at -68.29%.
Galena Biopharma (NASDAQ:GALE) : The consensus on Galena Biopharma (NASDAQ:GALE) based on 5 analyst recommendation on the company stock is 1.8, which is interpreted as a Buy recommendation. Zacks Investment Research has issued a rank of 4 which endorses a Sell on the stock. However, 3 brokers have a differing view as they consider the stock to be a Strong Buy at current levels. 2 experts consider that the stocks earnings and the quoted price is in harmony, hence, they give it a Hold rating.
Galena Biopharma (NASDAQ:GALE): During Thursdays trading session, Bulls were in full control of the stock right from the opening. The stock opened at $0.35 and $0.35 proved to be the low of the day. Continuous buying at higher levels pushed the stock towards an intraday high of $0.50. The buying momentum continued till the end and the stock did not give up its gains. It closed at $0.47, notching a gain of 33.17% for the day. The total traded volume was 50,523,786 . The stock had closed at $0.35 on the previous day.
In an insider trading activity, The Securities and Exchange Commission has divulged that Dunlap Ryan, officer (Former Chief Financial Officer) of Galena Biopharma, Inc., had unloaded 126,875 shares at an average price of $2.18 in a transaction dated on June 1, 2016. The total value of the transaction was worth $276,588.
Galena Biopharma, Inc. is a biopharmaceutical company. The Company is focused on developing and commercializing targeted oncology therapeutics. Its development portfolio ranges from mid- to late-stage clinical assets, including immunotherapy program led by its lead product NeuVax (nelipepimut-S), which is in Phase III clinical trial and is a targeted cancer immunotherapy. NeuVax is the immunodominant nonapeptide derived from the extracellular domain of the HER2 protein, a target for therapeutic intervention in breast and gastric carcinomas. GALE-301 is an immunogenic peptide and can stimulate cytotoxic T lymphocytes to recognize and destroy Folate Binding Protein-expressing cancer cells. GALE-401 is a controlled release formulation of anagrelide. Its commercial drug, Abstral (fentanyl) Sublingual Tablets is a treatment option for inadequately controlled breakthrough cancer pain.